2022.11.25
FIRST PATIENT IMPLANT IN THE FIRST-IN-MA···
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL
TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALV···
2022.11.14
FIRST PATIENT IMPLANT IN MULTI-CENTER RE···
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION
CLINICAL TRIAL OF PEIJIA HighLife® TRANSCATHETER···
2024.10.18
ONE-YEAR CLINICAL FOLLOW-UP RESULTS OF T···
From October 9-16, 2024, China Structural Week
2024 was grandly held. TaurusNXT® ❖ New Third-G···
2022.06.09
Peijia Medical Fluxcap® Balloon Guide Ca···
On June 8, 2022, Peijia Medical received the approval from the National Medical Products Administrat···
2022.05.24
Peijia Medical Tethys AS® Aspiration Cat···
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter Obta···
2022.02.17
NMPA Approval for Registration Applicati···
On February 11, 2022, Peijia Medical Limited (the “Company”) received the approval from the National···
2022.01.08
The First Clinical Case using HighLife T···
On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“···
2021.11.01
Peijia Medical Announces First Patient T···
A major breakthrough in interventional therapy for heart valve disease and an innovative progress in···
2021.09.14
Peijia Medical Announces First Patient I···
Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the···
2021.09.06
Peijia Medical Engages Professor Saibal ···
Peijia Medical Engages Professor Saibal Kar as Exclusive ConsultantTo Advise the Company’s Mitral Tr···
2021.08.09
TaurusOne® Valve clinical outcome publis···
TaurusOne® Valve clinical outcome published in EuroIntervention The first ever publication···
2021.06.26
With the second-generation transcatheter···
With the second-generation transcatheter aortic valve replacement system approved for marketing, Pei···